HER2-positive breast cancer survival period

HER2 positive breast cancer survival

1. In recent years, trastuzumab, lapatinib, pertuzumab, T-DM1, etc., targeting HER2 in breast cancer, have significantly prolonged the survival of patients with HER2-positive breast cancer.

2. However, with the advancement of science and technology, there is a special target HER2-positive drug application, the emergence of Herceptin, which can effectively reverse this HER2-positive disadvantage. As long as the resistance to HER2 can be regulated, this het2-positive has little effect on survival.

3. The survival time of HER2-positive breast cancer patients is related to the specific pathological stage.

Lung metastasis after breast cancer resection

Breast cancer patients with lung metastasis after surgery are now in the late stage of cancer and require combined treatment including chemotherapy, radiotherapy, targeted drug therapy, biological therapy and immunotherapy to control the disease, alleviate symptoms and prolong life.

Therefore, we need PET-CT or enhanced CT to determine whether it is lung metastasis. Small lung nodules after breast cancer surgery may be metastasis.